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ABSTRACT
A total of 104 patients, aged 18 to 70 years, with a diagnosis of chronic idiopathic myelofibrosis (CIMF),
polycythemia vera (PV), or essential thrombocythemia (ET) with marrow fibrosis were transplanted from
allogeneic (56 related and 45 unrelated) or syngeneic (n  3) donors. Busulfan (BU) or total body irradiation
(TBI)-based myeloablative conditioning regimens were used in 95 patients, and a nonmyeloablative regimen of
fludarabine plus TBI was used in 9 patients. The source of stem cells was bone marrow in 43 patients and
peripheral blood in 61 patients. A total of 63 patients were alive at a follow-up of 1.3–15.2 years (median, 5.3
years), for an estimated 7-year actuarial survival rate of 61%. Eleven patients had recurrent/persistent disease,
of whom 8 died. Nonrelapse mortality was 34% at 5 years. Patients conditioned with targeted BU (plasma levels
800–900 ng/mL) plus cyclophosphamide (tBUCY) had a higher probability of survival (68%) than other
patients. Dupriez score, platelet count, patient age, and comorbidity score were statistically significantly
associated with mortality in univariate models. In a multivariable regression model, use of tBUCY (P  .03),
high platelet count at transplantation (P  .01 for PV/ET; P  .39 for other diagnoses), younger patient age
(P  .04), and decreased comorbidity score (P  .03) remained statistically significant for improved survival.
Our findings show that hematopoietic cell transplantation offers potentially curative treatment for patients
with ICMF, PV, or ET.
© 2007 American Society for Blood and Marrow Transplantation
KEY WORDS
Myeloﬁbrosis ● Hematopoietic cell transplantation ● Polycythemia vera ● Essential thrombo-
cythemia
s
w
1
g
v
w
r
t
f
p
cNTRODUCTION
Chronic idiopathic myeloﬁbrosis (CIMF), also
nown as agnogenic myeloid metaplasia, is a clonal
hronic myeloproliferative disease characterized by
rogressive marrow ﬁbrosis, extramedullary hemato-
oiesis with splenomegaly, anemia, and leukoerythro-
lastosis [1]. The median survival after diagnosis of
IMF is 3.5–5 years. Clinical presentations are het-
rogeneous. Prognostic factors include anemia, leuko-
ytosis or leukopenia, clonal cytogenetic abnormali-
ies, and older age. According to the Dupriez scoring system, which uses hemoglobin of  100 g/L and
hite blood cell (WBC) counts 4 109/L or 30
09/L as risk factors, patients are divided into 3 risk
roups: low risk (no risk factors), with a median sur-
ival of 7–8 years; intermediate risk (1 risk factor),
ith a median survival of 2.2 years; and high risk (2
isk factors), with a median survival of slightly more
han 1 year [2]. This classiﬁcation, although developed
or conservatively managed patients, has also provided
rognostic information for allogeneic hematopoietic
ell transplantation (HCT). We and others have
hown that, depending on Dupriez risk group, 40%–
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D. M. B. Kerbauy et al.3560% of patients survive in remission after HCT [3-7].
nalysis of outcome data after HCT also suggests that
n addition to hemoglobin and WBC, low platelet
ounts are signiﬁcantly correlated with a lower prob-
bility of survival [5]. This observation agrees with a
ecent report from the Mayo Clinic showing that
ncluding platelet counts into the risk assessment of
atients with CIMF improves prognostic accuracy in
atients not undergoing transplantation [8]. Because
CT is currently the only therapy with curative po-
ential for CIMF, these data suggest that patients with
IMF who are candidates for transplantation should
e considered for transplantation before they develop
igh-risk features.
Myeloﬁbrosis may also occur in patients with
ther myeloproliferative disorders, particularly poly-
ythemia vera (PV) and essential thrombocythemia
ET). Although the overall prognosis for patients with
V or ET is much better than that for patients with
IMF, once myeloﬁbrosis develops, no currently
vailable treatment other than HCT has curative po-
ential. Thus, it is noteworthy that the most encour-
ging transplantation results in patients with myeloﬁ-
rosis have been achieved in those with a previous
iagnosis of PV or ET [9], although because of trans-
lantation-related mortality, the candidacy for and
iming of HCT have remained controversial.
Here we provide a summary of transplantation
esults from a single center in 104 patients with my-
loﬁbrosis.
ATIENTS AND METHODS
atient and Disease Characteristics
A total of 104 patients (57 females, 47 males) with
diagnosis of CIMF, post-PV or post-ET ﬁbrosis, or
yeloﬁbrosis associated with myeloproliferative dis-
rders not otherwise speciﬁed underwent HCT at the
red Hutchinson Cancer Research Center (FHCRC).
ifty-four of these patients have been described pre-
iously [5]. Patient and disease characteristics are sum-
arized in Table 1. All but 3 patients underwent
ransplantation after 1990. The patients ranged in age
rom 18 to 70 years (median, 49 years). The interval
rom diagnosis to transplantation ranged from 2 to
13 months (median, 15 months). The distribution by
upriez risk group and severity of bone marrow ﬁ-
rosis were similar to that in the original cohort of 54
atients; however, only 20% of patients in the new
ohort had splenectomy, compared with 38% of the
nitial 54 patients. Also, the median patient age was 44
ears in the original cohort but 53 years in the new
ohort (51.2 years when excluding 9 patients condi-
ioned with a nonmyeloablative regimen; see the fol-
owing).
Indications for HCT included peripheral blood
ytopenias, deﬁned as a hemoglobin 10 g/dL, plate- ret count  100  109/L, neutrophil count  1.5 
09, or evidence of leukemic transformation. In 5
atients, myeloﬁbrosis was possibly associated with
nother disease. One patient presented with bcr/abl-
egative CIMF but 18 months later developed evi-
ence of bcr/abl-positive CML; 1 patient was diag-
osed concurrently with non-Hodgkin lymphoma; 2
atients exhibited some dysplastic marrow morphol-
gy, including megakaryocytes, in the context of ex-
ensive marrow ﬁbrosis; and 1 patient had concurrent
diopathic thrombocytopenic purpura (ITP). Clonal
aryotypic abnormalities were documented in 45 pa-
ients: 8 ( other abnormalities) in 8 patients, 20q
 other abnormalities) in 6 patients, 7q ( other
bnormalities) in 2 patients, 13q ( other abnormal-
ties) in 2 patients, various translocations in 13 pa-
ients, and other structural or numeric abnormalities
n 14 patients. Karyotypes were normal in 53 patients,
nd in 6 patients, material was insufﬁcient for analysis.
total of 49 patients received transfusions of red
lood cells, platelets, or both; 43 received hydroxyu-
able 1. Patient and Disease Characteristics
Data
Number of
Patients
umber of patients studied 104
atient age, (years), range (median) 18-70(49)
atient sex, M/F 57/47
isease duration, (months), range
(median) 2-31(15)
rimary diagnosis
CIMF 62
ET with myelofibrosis 18
PV with myelofibrosis 12
Myelofibrosis with increased
blasts 7
Other* 5
egree of marrow fibrosis†
1 9
2 25
3 28
4 37
upriez risk classification at
transplantation
Low 44
Intermediate 40
High 20
latelet count at transplantation
> 100  109/L 70
< 100  109/L 34
revious splenectomy‡
Yes/no 29/69
One patient had CIMF that evolved to CML. One patient had a
concurrent diagnosis of non-Hodgkin’s lymphoma, and 2 pa-
tients showed myelodysplastic changes in addition to the typical
morphology of CIMF. One patient had idiopathic thrombocy-
topenic purpura in addition to marrow ﬁbrosis.
The degree of ﬁbrosis was graded as described previously [10].
Five patients were not classiﬁed.
Data were incomplete for 6 patients.ea, 20 received interferon, 16 received anagrelide, 15
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Transplantation for Myelofibrosis 357eceived corticosteroids, 26 received erythropoietin,
nd 19 received chemotherapy other than hydroxyu-
ea (30 patients received more than 1 agent); 12 re-
eived no therapy. Clinical, hematologic, and patho-
ogic disease characteristics were assessed by standard
rocedures as described previously [4,5]. Marrow ﬁ-
rosis was determined and staged as described previ-
usly [5,10]. All patients had given informed consent
ccording to the requirements of the FHCRC’s Insti-
utional Review Board, which conforms to the Hel-
inki Declaration.
onor Selection
Donor characteristics are summarized in Table 2.
onors ranged in age from 6 to 63 years (median, 41
ears); 52 were male and 52 female. Fifty-nine patients
ad related donors: HLA genotypically identical sib-
ings in 52, syngeneic twins in 3, and HLA-noniden-
ical family members in 4. Among the latter group, 1
iffered for an HLA-DR antigen, 1 differed for -DR
nd -DQ antigens, 1 differed for a -B antigen (in the
able 2. Donor and Transplant Characteristics
Data Number of Transplants
onor age (years), range (median) 6-63 (41)
onor sex, M/F 52/52
elationship
Related 59
HLA-identical sibling 52
HLA-nonidentical 4
Syngeneic 3
Unrelated* 45
HLA-identical 36
HLA-nonidentical 9
ource of stem cells
Marrow 43
Peripheral blood 61
onditioning regimens
BUCY/tBUCY 6/59
ATGtBUCY§ 14
BUTBI (1200) 9
CYTBI (1200) 6
FLUtBU 1
FLUTBI (200) 9
VHD prophylaxis
MTX  CSP 86
MMF  CSP 10
Other† 5
MV status, patient/donor‡
/ 20
/ 27
/ 12
/ 40
In 34 patients, high-resolution typing was performed: 27 were
HLA-identical and 7 were not; 9 donors were matched by
low/intermediate-level typing (see text for details).
One patient received MTX, 3 patients received MTX  CSP 
FK506, and 1 patient received MTX  CSP  MMF; 3 syn-
geneic recipients received no prophylaxis.
Information was missing in 5 patients.
aATG/thymoglobulin.ost-versus-graft direction), and 1 differed for -C and
B antigens (in the GVH direction). Unrelated donors
ere identiﬁed for 45 patients. High-resolution
LA-A, -B, -C, -DRB1, and -DQB1 allele typing was
vailable in 34 patients, and 27 of these were HLA-
dentical with the recipients. Among the 18 donors
ho were not identical with the patients or had not
ndergone high-resolution typing, 9 were matched
ith their recipients by low- or intermediate-level
yping. Another 7 were HLA-nonidentical by high-
esolution typing (HLA-A locus in 3, -B locus in
, -DQ locus in 1, and -DR plus -DQ loci in 1). The
LA data were incomplete in 2 donor–recipient pairs,
nd thus the degree of match or mismatch could not
e determined in these 2 pairs.
ematopoietic Cell Transplantation
Transplantation characteristics are summarized in
able 2. The conditioning regimens used were deter-
ined by sequential protocols that were active at the
ime of HCT. A total of 59 patients were conditioned
ith busulfan (BU) 16  1 mg/kg orally over 4 days,
ith dose adjustments made to achieve steady-state
lasma levels of 800–900 ng/mL, plus CY 120 mg/kg
tBUCY). Six patients received BU 16 mg/kg (without
argeting) plus CY 120 mg/kg (BUCY). Fifteen pa-
ients received total body irradiation (TBI) 6  200
Gy in combination with either BU 7 mg/kg (9 pa-
ients) or CY 120 mg/kg (6 patients), as described
reviously [5,11-14]. Fourteen patients (all in the new
ohort) received tBUCY plus thymoglobulin (THY)
.5 mg/kg over 3 days [15]. Nine patients (all in the
ew cohort) received nonmyeloablative conditioning
ith ﬂudarabine (Flu) 90 mg/m2 intravenously (IV)
nd TBI 200 cGy, because of older age (range, 41–70
ears; median, 60 years) or concurrent nonhemato-
ogic disease [16], and 1 patient received Flu 120
g/m2 IV over 4 days, along with tBU [17].
A total of 43 patients received marrow, and 61
eceived G-CSF–mobilized peripheral blood progen-
tor cells (PBPCs) as a stem cell source. Graft-versus-
ost disease (GVHD) prophylaxis consisted of cyclo-
porine (CSP) and methotrexate (MTX) in 86
atients, mycophenolate mofetil (MMF) and CSP in
0 patients, MTX only in 1 patient, and various com-
inations of MTX or MMF and a calcineurin inhibi-
or in 4 patients [18,19]. Three syngeneic transplant
ecipients received no GVHD prophylaxis.
riteria for Engraftment and Response
Time to engraftment was deﬁned by the ﬁrst of 3
onsecutive days on which the absolute neutrophil count
eached 0.5  109 /L [20]. Chimerism determinations
n marrow cells were carried out at 28 and 100 days
osttransplantation, again at 1 year posttransplantation,
nd at irregular intervals thereafter. GVHD was diag-
n
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D. M. B. Kerbauy et al.358osed based on previously established criteria [21,22].
urvival time was the time from transplantation until
eath or date of last contact (at which time patients
ere censored). Relapse-free survival was the time
rom transplantation until relapse or death from non–
elapse-related causes. Relapse was deﬁned as the re-
ppearance of host cells and morphologic criteria of
yeloﬁbrosis after initial clearing of the marrow or
he detection of previously existing cytogenetic abnor-
alities [5]. In some patients, relapse could not be
etermined deﬁnitively, because they showed reemer-
ence of host cells (mixed chimerism) but no evidence
f disease recurrence (see Results).
etermination of Comorbidities
Comorbid conditions were assessed by a compre-
ensive review of medical records in a computerized
atabase. Scores were assigned by a single investigator
M.S.) blinded to outcome data, using the HCT-spe-
iﬁc comorbidity index (HCT-CI) [16] developed by
odifying the Charlson Comorbidity Index [23]. The
odiﬁcations included a reﬁnement of some co-
orbidity deﬁnitions by incorporating laboratory
ata, adding new comorbidities, and calculating new
eights for comorbidities relevant for HCT recip-
ents. The HCT-CI was shown to have greater
ensitivity and higher predictive power for HCT
utcomes than the original index [16].
tatistical Analysis
The association of various baseline characteristics
ith the hazard of overall mortality was examined by
tting Cox regression models [24]. Estimates of over-
ll survival were obtained using the Kaplan and Meier
ethod [25]. All 2-sided P values from regression
odels were estimated from the Wald test, with no
djustments made for multiple comparisons. Results
ere analyzed as of June 30, 2005.
ESULTS
ngraftment
A total of 101 patients could be evaluated for
ngraftment. Among allogeneic HCT recipients con-
itioned with regimens other than Flu  TBI (non-
yeloablative), the median time to granulocyte en-
raftment was 19 days. Patients who received PBPCs
ngrafted an average of 5.7 days earlier than those
ho received marrow (P  .002). Patients who under-
ent splenectomy engrafted an average of 2.6 days
arlier than those with intact spleens (P  .18); and
his difference was increased to 3.6 days (P .05) after
djusting for source of stem cells. The difference be-
ween PBPCs and marrow did not change signiﬁcantly
fter adjusting for splenectomy. mraft Failure and Relapse
Seven patients experienced graft failure as doc-
mented by declining blood cell counts and reemer-
ence of host cells in blood and marrow after initial
ngraftment. Four received transplants from HLA-
onidentical donors (3 family members and 1 unre-
ated). Three of these patients were conditioned
ith tBUCY and 1 was conditioned with CYTBI,
nd all 4 received marrow as a source of stem cells.
he remaining 3 patients received transplants from
LA-identical unrelated donors, 2 after nonmy-
loablative conditioning and 1 after tBUCY plus
hymoglobulin; all 3 received PBPCs. Three among
he 7 patients with graft failure experienced relapse,
died of non–relapse-related causes, and 1 was alive
ith autologous marrow recovery and no evidence
f disease.
Another 6 patients were mixed chimeras at the
-month evaluation. Among these, 2 subsequently lost
heir grafts and relapsed, and 2 converted to full donor
himerism and were alive in remission. Two patients
emained mixed chimeras, with 100% CD33 cells at
years after HCT and 7%–34% CD3 donor cells at
and 11 years after HCT, respectively.
Thus, a total of 11 patients did not achieve sus-
ained complete donor cell engraftment. Among
hese, 3 were alive with normal hematopoietic param-
ters (2 mixed chimeras and 1 with autologous recov-
ry), 5 experienced relapse, and 3 died from non–
elapse-related causes. In addition, 4 patients relapsed
fter having achieved complete donor cell chimerism.
f the 11 patients with relapse overall (including the
patients surviving with mixed chimerism), 9 had
IMF, 1 had PV, and 1 had ET. One of the 11
atients who relapsed achieved complete remission
hile developing GVHD on tapering CSP and sur-
ived in remission, whereas 8 patients died with re-
apsed disease.
VHD
Overall, 65 of 99 evaluable patients (64%) given
llogeneic transplants developed acute GVHD (grade
I in 44, grade III in 19, and grade IV in 2), for
ncidences of 58% (29 of 50) among recipients of
LA-identical sibling transplants and 73% (36 of 49)
mong unrelated (both HLA-identical and nonidenti-
al) or mismatched family member transplants. There
as a trend toward less GVHD in HLA-identical
ibling transplants (P  .11). Chronic GVHD oc-
urred in 85 patients (84%) and was extensive, requir-
ng therapy, in 62 (59%). No statistically signiﬁcant
ifference was seen between HLA-identical sibling
56%) and unrelated donor or mismatched family
ember transplants (59%).
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Transplantation for Myelofibrosis 359auses of Death
Causes of death are summarized in Table 3.
ight patients (1 syngeneic transplant and 7 alloge-
eic transplant recipients) died from relapse, and 33
ied from non–relapse-related causes, 14 of these
ithin 100 days of transplantation (day 100 mortal-
ty, 13%). The projected non–relapse-related mor-
ality at 5 years was 34% (95% conﬁdence interval
CI]  28%–48%). The median time to relapse was
.8 years.
urvival and Disease Response
A total of 63 patients were alive at last contact, for
n estimated probability of survival of 61% (95%
I 43%–65%) at 5 years (Figure 1A). Among these,
7 were conditioned with myeloablative regimens and
eceived transplants from allogeneic donors, 1 re-
eived a syngeneic transplant, and 5 underwent trans-
lantation after nonmyeloablative conditioning. Uni-
ariate regression models for overall mortality are
ummarized in Table 4. Patients conditioned with
BUCY had a higher probability of survival (68%)
han those conditioned with other regimens (46%;
azard ratio [HR] for mortality  0.4; 95% CI 
.2–0.7; P  .001) (Figure 1B). Patients who had
eceived antithymocyte globulin (ATG) in addition to
BUCY (n  14) had a higher HR for mortality than
hose conditioned with tBUCY without added ATG
HR  1.92; 95% CI  0.74–4.98), although the
ifference was not statistically signiﬁcant (P .18). Of
he 13 patients receiving transplants from HLA-non-
dentical (related or unrelated) donors, 7 survived for
probability of 51% at 3 years. Among 9 patients
onditioned with a low-intensity regimen of ﬂudara-
ine and TBI, 5 (56%) are surviving. Patients in
igher Dupriez risk groups had higher mortality rates,
nd patients with less extensive ﬁbrosis tended to fare
omewhat better than patients with more extensive
brosis, although the difference was not statistically
igniﬁcant (Table 4). Patients with leukemic transfor-
able 3. Causes of Death
Causes of Death Number of Patients
rogressive disease/relapse* 8
onrelapse causes 33
Pneumonia/pulmonary failure 12
MOF/HUS/TTP 5
Invasive aspergillosis  GVHD 7
GVHD† 6
Miscellaneous‡ 3
OF indicates multiorgan failure; HUS, hemolytic uremic syn-
drome; TTP, thrombotic thrombocytopenic purpura.
Two patients relapsed with lymphoma (see text).
Including 1 patient with bronchiolitis obliterans.
Two patients died of sepsis, and 1 patient died of viral encephalitis.ation tended to have a higher mortality rate than ohose without, although the numbers were small, and
he difference did not achieve statistical signiﬁcance
HR 2.1; 95% CI 0.8–5.3; P .12). Results in 92
atients without leukemic transformation who re-
eived allogeneic transplants after myeloablative reg-
mens are summarized in Figure 2. Mortality was
lightly higher in patients receiving transplants from
nrelated donors (HLA-identical by high-resolution
yping) than in patients receiving transplants from
enotypically HLA-identical siblings, but the differ-
nce was not statistically signiﬁcant (HR  1.4; 95%
I  0.6–3.4; P  .42; Figure 3). After adjusting for
atient age, HCT-CI, and conditioning regimen, the
agnitude of the difference was reduced to HR 1.2.
Patients with an underlying diagnosis of PV or ET
ad a signiﬁcantly lower hazard of mortality than
atients with other diagnoses (P  .03; Table 4) and
ence superior survival, as shown in Figure 4. In a
ultivariable analysis, conditioning with tBUCY con-
inued to be associated with a decreased hazard of
ortality (Table 5). In addition, because there was a
orrelation between the underlying diagnosis and
latelet counts (only 3 of 34 patients with low platelet
igure 1. Overall survival. (A) All patients in the study (n  104)
ompared to patients given allogeneic transplants after myeloabla-
ive conditioning regimens (n  92). (B) Survival among the 92
llogeneic recipients prepared with myeloablative regimens by type
f regimen.
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D. M. B. Kerbauy et al.360ounts carried a diagnosis of PV or ET), we consid-
red the following variables: PV or ET plus high
latelet count, diagnoses other than PV or ET plus
igh platelet count, and any diagnosis with low plate-
et count (Table 5). In this comparison among patients
ith high platelet counts, patients with PV or ET had
lower hazard of mortality than patients with other
able 4. Univariate Regression Models for Overall Mortality
Factor (Number of Patients Dying/All Patients)
onditioning regimen*
Other regimens (24/45)
Targeted BUCY (18/59)
onditioning regimen†
Targeted BUCY (18/59)
Other ablative regimens (20/36)
Nonablative (4/9)
latelet count
100  109/L or higher (25/70)
< 100  109/L (17/34)
upriez risk classification
Low (11/44)
Intermediate (19/40)
High (12/20)
upriez risk classification
Low
Intermediate/high
ge, modeled as a continuous linear variable
ge, by cohort
Younger than 40 (6/22)
40–50 (14/35)
Older than 40 (22/47)
egree of fibrosis
1–2 (11/34)
3 (14/28)
4 (15/37)
aryotype
Clonal (21/45)
Normal (20/53)
plenectomy
No (32/69)
Yes (9/29)
ource of stem cells
PBPC (23/61)
Marrow (19/43)
onor
Related HLA-identical or syngeneic (20/55)
Unrelated or mismatched related (22/49)
isease duration, modeled as continuous linear variable
vidence of transformation to leukemia
No
Yes
iagnosis
PV/ET
Other diagnoses
CT-CI, modeled as continuous linear variable
CT-CI
0–3
4–6
tBUCY versus all other regimens.
Separate consideration of patients conditioned with a nonmyeloab
HR  1 indicates superior outcome; 1, inferior outcome.iagnoses, and both had lower hazards compared with datients with low platelet counts (HR  0.3; 95%
I  0.1–0.8; P  .01 and HR  0.7 95% CI 
.4–1.5; P  .39; Table 5). The small number of
atients with an HCT-CI of 4–6 (n  12) had a
igher risk of death than did those with a score of 0–3
HR  2.3; P  .03; Table 5). After adjusting for
onditioning regimen, patient age, HCT-CI, and the
Hazard Ratio‡ 95% CI P
1 — —
0.4 0.2–0.7 .001
1 — —
2.6 1.4–4.9 .003
2.9 1.1–7.8 .04
1 — —
2.1 1.1–3.8 .02
1 — —
2.3 1.1–4.9 .02
2.8 1.2–6.3 .01
1 — —
2.5 1.3–4.9 .009
asing age, increasing hazard — .01
1 — —
1.5 0.6–3.8 .35
2.1 0.9–5.0 .09
1 — —
1.9 0.9–4.2 .11
1.5 0.7–3.2 .33
1 — —
0.8 0.37–1.26 .22
1 — —
0.6 0.3–1.2 .16
1 — —
1.1 0.6–2.0 .76
1 — —
1.4 0.8–2.5 .28
— — .53
1 — —
2.1 0.8–5.3 .12
1 — —
2.4 1.1–5.5 .03
asing score, increasing hazard — .02
1 — —
2.6 1.3–5.6 .01
regimen.Incre
Incre
lativeiagnosis/platelet count variable, the impact of Du-
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Transplantation for Myelofibrosis 361riez risk group was no longer statistically signiﬁcant
P  .28; modeled as continuous variable).
Hematologic parameters in surviving patients (last
vailable determination at 5 months–11 years after
CT) included white blood cell counts of 1.9–25 
igure 2. Impact of disease parameters on survival (same patients as
n Figure 1). (A) Effect of Dupriez risk category. (B) Effect of the
egree of marrow ﬁbrosis (not graded in 5 patients).
igure 3. Overall survival among patients without leukemic
ransformation conditioned with myeloablative regimens and
ransplanted from HLA-identical sibling donors (n  47) or
nrelated donors who were HLA-identical by high-resolutiontyping (n  20).09/L (median, 6.2  109/L), absolute neutrophil
ounts of 0.3–9.0  109/L (median, 3.3  109/L),
latelet counts of 50–1167  109/L (median, 190 
09/L), and hemoglobin levels of 9–17 g/dL (median,
2.6 g/dL). The lowest blood cell counts were seen in
atients with the shortest follow-up and those with
ixed chimerism.
Posttransplantation marrow biopsy specimens
ere available in 82 patients surviving beyond 100
ays. Among these, 42 showed no ﬁbrosis or only
races of ﬁbrosis; 19 were staged as grade 1 ﬁbrosis, 14
s grade 2 ﬁbrosis, and 5 as grade 3–4 ﬁbrosis. In 2
atients, residual osteosclerosis was present but with
o evidence of reticulin ﬁbrosis. In the presence of
00% donor cell chimerism and normal blood cell
ounts or transfusion independence, the persistence of
brosis (or osteosclerosis) by itself was not considered
o represent relapse or persistent disease.
Among 66 patients with intact spleens and
plenomegaly who survived beyond 100 days after
ransplantation, the spleen was of normal size in 50
atients at the time of the latest examination, be-
ween 6 months and 3 years after HCT. In 4 pa-
ients, the spleen was palpable at the costal margin;
n 2 it was enlarged but  8 cm, and in 4 it was 
cm. In 3 patients, the spleen was reported to be
alpable, but no size was recorded, and in 3 other
atients, no information on spleen size was available.
ISCUSSION
The present study conﬁrms the curative potential
f HCT for patients with myeloﬁbrosis, with com-
lete remission now extending up to 15 years in some
atients. Survival was comparable in patients receiving
ransplants from HLA genotypically identical siblings
nd those receiving transplants from HLA-identical
nrelated donors. The number of HLA-nonidentical
igure 4. Impact of primary diagnosis on transplantation outcome
same patients as in Figure 1).ransplants was too small to allow us to draw ﬁrm
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D. M. B. Kerbauy et al.362onclusions, however. As in numerous other studies,
he probability of successful transplantation declined
ith increasing patient age [26,27].
Similar to our previous report, Dupriez risk group
as a signiﬁcant factor for transplantation outcome in
nivariate analysis, although differences between the 3
isk groups were not statistically signiﬁcant in a mul-
ivariable regression model. However, this observa-
ion does not exclude the possibility that Dupriez risk
ffected transplantation outcome, because the Du-
riez parameters are likely to interact with other pa-
ameters, such as pre-HCT platelet count, which has
een shown to be of prognostic signiﬁcance by Dingli
t al. [8] and to be correlated with survival after HCT
n the present study. Therefore, clinical changes re-
ected in Dupriez risk group should be monitored,
nd progression should lead to the consideration of
ransplantation. Moreover, because 1/3 of patients in
he present study carried diagnoses other than CIMF
for which the Dupriez classiﬁcation was developed),
ifferent categorizations of disease groups may be
ndicated. In fact, a high pretransplantation platelet
ount, particularly in patients with PV or ET, was
ssociated with a signiﬁcantly reduced overall mortal-
ty. This ﬁnding was in agreement with observations
n our initial report, where the hazard of transplanta-
ion-related mortality correlated inversely with plate-
et counts at the time of HCT [5].
Another disease parameter previously shown to
ffect posttransplantation prognosis was the degree of
arrow ﬁbrosis [4,5]. The present analysis again sug-
ested such an effect, although it was less prominent
han described initially (possibly related to the fact
hat there were 4 deaths from various causes among
he 9 patients with the lowest degree of marrow ﬁbro-
is) [4,5]. Nevertheless, the role of ﬁbrosis in trans-
lantation outcome remains controversial in view of
he considerable variation in sampling by single mar-
ow biopsies and various classiﬁcation schemes used
10,28]. Methods that assess larger volumes of mar-
able 5. Multivariable Regression Models for Overall Mortality
Factor
onditioning regimen
Other regimens
Targeted BUCY
iagnosis/platelet count
Low platelet count
PV/ET, high platelet count
Other diagnoses, high platelet count
ge, continuous linear variable Increasin
CT-CI
0–3
4–6
dditional variables, such as Dupriez score, splenectomy, normal ka
duration, did not statistically signiﬁcantly improve the model.ow, such as magnetic resonance imaging (MRI), may ymprove the ability to more reliably classify marrow
brosis [29]. Indeed, a recent report suggests that
RI is useful not only in assessing the extent of
brosis, but also in monitoring regression of ﬁbrosis
fter HCT [30].
As expected, patients who underwent transplanta-
ion because of leukemic transformation did less well
han patients who did so because of peripheral blood
ytopenias associated with marrow ﬁbrosis. However,
he major causes of death were organ toxicity and
nfections, rather than relapse, conceivably because
hese patients had received pretransplantation cyto-
oxic therapy. Alternatively, these patients had more
dvanced disease with associated extramedullary he-
atopoiesis, which is known to be associated with
eactive ﬁbrosis in the liver and lung, rendering those
rgans susceptible to regimen-related toxicity.
In agreement with previous data, there was an
dvantage (insigniﬁcant) for the tempo of engraftment
n splenectomized patients, an effect that was more
rominent after adjusting for the source of stem cells.
n patients with intact spleens, there was no signiﬁcant
orrelation between spleen size and the tempo of en-
raftment. Neither overall survival nor progression-
ree survival was affected by splenectomy. As in our
nitial report [5], the present data do not support the
outine use of preemptive splenectomy as a strategy to
mprove HCT outcome.
The prognostic relevance of clonal cytogenetic
bnormalities in patients with CIMF has been a mat-
er of debate. A recent report by Tefferi et al. [31]
uggests that the presence of del (20q) or del (13q) in
IMF carries a favorable prognosis. In the present
tudy, clonal cytogenetic abnormalities did not signif-
cantly affect overall outcome. Of 8 patients with del
20q) or del (13q), 6 are surviving in remission; these
umbers are too few to allow a ﬁrm conclusion. The
ecently described activating mutation (V617F) in
AK2, which is located on chromosome 9p [32], and
or which data were not available in the present anal-
rd Ratio 95% CI P
1 — —
0.5 0.3–0.9 .03
1 — —
0.3 0.1–0.8 .01
0.7 0.4–1.5 .39
increasing hazard — .06
1 — —
2.3 1.1–4.9 .03
e, degree of ﬁbrosis, unrelated donor, stem cell source, and diseaseHaza
g age,
ryotypsis, may affect the tempo of progression of ﬁbrosis
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Transplantation for Myelofibrosis 363nd may have a more profound effect on prognosis
han clonal chromosomal ﬁndings that have been in-
estigated in the past [32,33].
Finally, older patient age was associated with sig-
iﬁcantly increased posttransplantation mortality. Be-
ause patients with myeloﬁbrosis tend to be in an age
ange in which high-dose therapy generally is not well
olerated, this is an important observation in regard to
he selection of transplantation conditioning regi-
ens. As shown in earlier trials [11,34], the condition-
ng regimen had a signiﬁcant effect on HCT outcome,
ith the highest success rate obtained with a targeted
UCY regimen. Overall survival with this regimen in
he new cohort of patients was not statistically signif-
cantly different from that in the originally reported
ohort (P  .28), even though the median age in the
ew cohort was almost 1 decade older. Nevertheless,
on–relapse-related mortality was 13% at day 100 and
4% at 5 years, raising the question as to whether
esults could be further improved with the use of
ower-intensity/nonmyeloablative conditioning regi-
ens. Rondelli et al. [7] recently reported 80% sur-
ival in 22 patients with myeloﬁbrosis who underwent
ransplantation at several institutions after condition-
ng with Flu, Cy, TBI, melphalan, or thiotepa in
arious combinations. Kroger et al. [6] presented data
rom a pilot study in 21 patients with myeloﬁbrosis
anging in age from 32 to 63 years (median, 53 years)
onditioned with BU 10 mg/kg plus Flu 180 mg/m2
nd ATG and receiving transplants from related or
nrelated donors. With a follow-up of 4–59 months,
he estimated 3-year relapse-free survival was 84%.
hese are very encouraging data. A nonmyeloablative
egimen of Flu/TBI, as used in the present study,
ielded a somewhat lower survival rate (56%), which
id not differ from that achieved with more conven-
ional regimens. However, this small cohort com-
rised patients up to age 70, most of whom had co-
orbid conditions [16] not present in the patients
eported by Kroger et al. [6]. That comorbid condi-
ions are relevant to the success of transplantation is
upported by the current analysis, which showed a
igniﬁcant effect of the HCT-CI on survival; even
mong the 9 patients conditioned with a nonmyeloa-
lative regimen, 3 died from transplantation-related
omplications. It is also important to note that the
ctual intensities of the conditioning regimens used
n these studies differed. Conceivably, conditioning
egimens of intermediate intensity will offer opti-
um results [35]. However, retrospective compari-
ons have yielded equivocal results [36-38], and only
rospective trials will be able to determine the op-
imum approach [39].
Overall, 33 patients in the present study died
rom non–relapse-related causes for a cumulative
ncidence of 34% at 5 years, similar to previous
eports [4,5]. Disease recurrence, on the other pand, was a relatively infrequent cause of death
7%). The estimated probability of relapse was 11%
t 5 years, an indication that the conditioning reg-
mens used along with the allogeneic effects of do-
or cells were effective in eradicating the disease in
ost patients. However, a few patients became
ong-term mixed chimeras. Cytogenetic markers
ere not available in these patients, and it was not
ossible to determine whether the original disease
lone was present. It is not clear whether or not the
ersistent host cells have malignant potential, and
urther observation is needed.
Thus, this study, with follow-up extending to 15
ears after HCT, conﬁrmed that HCT offers poten-
ially curative therapy for patients with myeloﬁbrosis
f various etiologies. The optimum timing for trans-
lantation remains to be determined, although the
ata suggest that higher success rates can be expected
t earlier disease stages. Indicators such as Dupriez
lassiﬁcation may help in determining the optimum
iming of transplantation. However, although earlier
CT tends to result in better outcome, patients with
ower Dupriez scores also may enjoy longer survival
ith conservative management [2,40]. Monitoring of
atients with CIMF for disease progression by, for
xample, sequential determination of peripheral blood
D34 cell counts [41], which were not available in
he present analysis, or MRI of the marrow for
hanges in the extent of ﬁbrosis, may reveal disease
rogression and facilitate the decision in terms of
CT. The optimum conditioning regimen may de-
end on patient age and comorbid conditions [42]. To
hat extent recent insights into the role of activating
utations in the tyrosine kinase JAK2 in patients with
yeloproliferative disorders will affect treatment de-
isions remains to be determined.
In summary, although questions remain in terms
f the timing of HCT and optimization of condition-
ng regimens, HCT clearly has curative potential for
atients with myeloﬁbrosis and promotes long-term
urvival in remission.
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